167 related articles for article (PubMed ID: 27013005)
21. How to select the right patients for focal therapy of prostate cancer?
Passoni NM; Polascik TJ
Curr Opin Urol; 2014 May; 24(3):203-8. PubMed ID: 24625428
[TBL] [Abstract][Full Text] [Related]
22. Percutaneous Irreversible Electroporation for Recurrent Thyroid Cancer--A Case Report.
Meijerink MR; Scheffer HJ; de Bree R; Sedee RJ
J Vasc Interv Radiol; 2015 Aug; 26(8):1180-2. PubMed ID: 26210244
[TBL] [Abstract][Full Text] [Related]
23. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-Intermediate Risk Prostate Cancer. Letter.
Jin S; Wu L; Mai Z; Yan W
J Urol; 2023 May; 209(5):846-847. PubMed ID: 36927011
[No Abstract] [Full Text] [Related]
24. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.
Zhang K; Teoh J; Laguna P; Ng CF; Rosette J
J Urol; 2023 May; 209(5):847-848. PubMed ID: 36927010
[No Abstract] [Full Text] [Related]
25. Optimal parameters for the destruction of prostate cancer using irreversible electroporation.
Rubinsky J; Onik G; Mikus P; Rubinsky B
J Urol; 2008 Dec; 180(6):2668-74. PubMed ID: 18951581
[TBL] [Abstract][Full Text] [Related]
26. Prostate Cancer Recurrence and Persistence After Irreversible Electroporation Focal Ablation.
Isharwal S; Greene KL
JAMA Surg; 2023 Apr; 158(4):349. PubMed ID: 36723928
[No Abstract] [Full Text] [Related]
27. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences?
Vroomen LGPH; Petre EN; Cornelis FH; Solomon SB; Srimathveeravalli G
Diagn Interv Imaging; 2017 Sep; 98(9):609-617. PubMed ID: 28869200
[TBL] [Abstract][Full Text] [Related]
28. An update on irreversible electroporation of liver tumours.
Yeung ES; Chung MW; Wong K; Wong CY; So EC; Chan AC
Hong Kong Med J; 2014 Aug; 20(4):313-6. PubMed ID: 24914075
[TBL] [Abstract][Full Text] [Related]
29. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
30. Focal therapy of prostate and kidney cancer.
Aminsharifi A; de la Rosette J; Polascik TJ
Curr Opin Urol; 2018 Nov; 28(6):491-492. PubMed ID: 30239417
[No Abstract] [Full Text] [Related]
31. [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].
Wiggermann P; Brünn K; Bäumler W
Radiologe; 2017 Aug; 57(8):637-640. PubMed ID: 28477079
[TBL] [Abstract][Full Text] [Related]
32. [Irreversible electroporation. Current value for focal treatment of prostate cancer].
Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB;
Urologe A; 2015 Jun; 54(6):854-62. PubMed ID: 26024649
[TBL] [Abstract][Full Text] [Related]
33. Focal irreversible electroporation for treatment of primary and radio-recurrent prostate cancer - the evidence is mounting!
Yaxley JW
BJU Int; 2023 Jun; 131 Suppl 4():32-33. PubMed ID: 36880114
[No Abstract] [Full Text] [Related]
34. Therapeutic potential of irreversible electroporation in sarcoma.
Yu Z; Zhang X; Ren P; Zhang M; Qian J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):177-84. PubMed ID: 22316365
[TBL] [Abstract][Full Text] [Related]
35. Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer.
Habibian DJ; Katz AE
Int J Hyperthermia; 2016 Nov; 32(7):795-800. PubMed ID: 27362886
[TBL] [Abstract][Full Text] [Related]
36. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Willemse PM; van Poppel H; Mottet N
Eur Urol; 2018 Jul; 74(1):84-91. PubMed ID: 29373215
[TBL] [Abstract][Full Text] [Related]
37. Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma.
Lencioni R; Crocetti L; Narayanan G
Tech Vasc Interv Radiol; 2015 Sep; 18(3):135-9. PubMed ID: 26365542
[TBL] [Abstract][Full Text] [Related]
38. [The outbreak of focal therapy for localized prostate cancer management].
Bozzini G; Colin P; Betrouni N; Ouzzane A; Puech P; Villers A
Rev Prat; 2013 Apr; 63(4):489-93. PubMed ID: 23682475
[TBL] [Abstract][Full Text] [Related]
39. Irreversible Electroporation of Prostate Cancer: Patient-Specific Pretreatment Simulation by Electric Field Measurement in a 3D Bioprinted Textured Prostate Cancer Model to Achieve Optimal Electroporation Parameters for Image-Guided Focal Ablation.
Wendler JJ; Klink F; Seifert S; Fischbach F; Jandrig B; Porsch M; Pech M; Baumunk D; Ricke J; Schostak M; Liehr UB
Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1668-1671. PubMed ID: 27256102
[No Abstract] [Full Text] [Related]
40. Irreversible Electroporation for Colorectal Liver Metastases.
Scheffer HJ; Melenhorst MC; Echenique AM; Nielsen K; van Tilborg AA; van den Bos W; Vroomen LG; van den Tol PM; Meijerink MR
Tech Vasc Interv Radiol; 2015 Sep; 18(3):159-69. PubMed ID: 26365546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
